```html

Coccidioidomycosis (Valley Fever) – A Comprehensive Medical Guide

Overview

Coccidioidomycosis, commonly called Valley fever, is an infection caused by the fungi Coccidioides immitis or Coccidioides posadasii. These organisms live in the soil of specific arid and semi‑arid regions of the western United States, Mexico, Central and South America, and parts of the Caribbean. When the soil is disturbed—by wind, construction, farming, or digging—spores become airborne and can be inhaled.

Most people who inhale the spores develop either no symptoms or a mild, flu‑like illness that resolves on its own. However, a minority develop moderate to severe disease, and a small percentage progress to disseminated infection that can affect the skin, bones, joints, or the central nervous system.

Who is affected? Valley fever is most common among adults aged 20‑60, but anyone can be infected. Certain groups have a higher risk of severe disease:

• People of African, Hispanic, or Filipino ancestry
• Individuals with weakened immune systems (e.g., HIV/AIDS, organ transplant recipients, chemotherapy patients)
• Pregnant women in the third trimester
• Older adults (>65 years)

Prevalence – In the United States, an estimated CDC data indicate >30,000 reported cases per year, but the true incidence is likely >150,000 because many infections go undiagnosed. The highest rates are in Arizona (≈ 300 cases per 100,000 population) and California’s Central Valley.

Symptoms

Symptoms vary widely depending on the location of infection (pulmonary vs. disseminated) and the host’s immune response. Below is a complete list with brief descriptions.

Pulmonary (lung) disease – most common form

• Fever – low‑grade to high, often accompanied by chills.
• Dry cough – may become productive with sputum.
• Chest pain – typically pleuritic (sharp pain with deep breaths).
• Shortness of breath – mild to moderate dyspnea.
• Fatigue – persistent tiredness that can last weeks.
• Headache – usually diffuse, not localized.
• Muscle or joint aches (myalgia/arthralgia).
• Rash – “erythema nodosum” (tender red nodules, usually on shins) is characteristic of early infection.
• Night sweats – especially in more severe cases.

Disseminated disease – infection spreads beyond the lungs

• Skin lesions – painless, raised, ulcerated or wart‑like bumps; can be papules, nodules, or pustules.
• Bone pain – often in the ribs, spine, or long bones; may lead to pathologic fractures.
• Joint swelling – mono‑ or oligo‑articular arthritis.
• Central nervous system involvement – meningitis presents with severe headache, neck stiffness, photophobia, or altered mental status.
• Chronic cough lasting >3 months – may indicate progressive pulmonary fibrosis.
• Weight loss and loss of appetite.

Symptoms usually appear 1–3 weeks after exposure, but incubation can range from 5 days to several months.

Causes and Risk Factors

What causes Valley fever?

The disease is caused by inhalation of airborne arthroconidia (spores) of Coccidioides spp. Once in the lungs, the spores transform into spherules that enlarge, rupture, and release endospores, propagating the infection. In some individuals, the immune response contains the infection; in others, the fungus spreads via blood or lymphatics.

Key risk factors

• Geography – Living in or traveling to endemic areas (Arizona, California’s Central Valley, Nevada, New Mexico, Texas, Utah, parts of Mexico and Central/South America).
• Environmental disturbance – Construction sites, farming, digging, windstorms, or dust storms that aerosolize spores.
• Immune suppression – HIV/AIDS, corticosteroids, biologic agents (e.g., TNF‑α inhibitors), solid organ transplant, hematologic malignancies.
• Pregnancy – Hormonal changes can dampen cell‑mediated immunity, especially in the third trimester.
• Ethnicity – African‑American, Filipino, Hispanic ancestry is linked to higher rates of severe disease.
• Age – Children <5 years and adults >65 years have increased risk of complications.

Diagnosis

Because early symptoms mimic flu or pneumonia, a high index of suspicion is essential for anyone with compatible exposure history.

Clinical evaluation

• Detailed exposure history (travel, work, outdoor activities).
• Physical exam focused on respiratory findings, skin lesions, joint swelling, and neurologic status.

Laboratory and imaging studies

• Serologic testing – Enzyme immunoassay (EIA) for IgM and IgG antibodies; complement fixation (CF) titers help gauge disease severity.
• Fungal culture – Sputum, bronchoalveolar lavage (BAL), or tissue biopsies; requires biosafety level 3 laboratory due to aerosol risk.
• Polymerase chain reaction (PCR) – Detects Coccidioides DNA; increasingly used for rapid diagnosis.
• Histopathology – Tissue stained with special fungal stains (Gomori methenamine silver or PAS) shows characteristic spherules.
• Chest radiograph – May show infiltrates, nodules, cavities, or hilar lymphadenopathy.
• CT scan of the chest – Provides detailed assessment of cavities, fibrosis, or disseminated lesions.
• Lumbar puncture – If meningitis is suspected; CSF analysis often shows lymphocytic pleocytosis, low glucose, and elevated protein, plus positive CSF serology.

Because serologies may be negative early in infection, repeat testing after 2–3 weeks is recommended if suspicion remains high.

Treatment Options

Treatment decisions depend on disease severity, patient immune status, and presence of dissemination.

1. Mild to moderate pulmonary disease (most healthy adults)

• Supportive care – Rest, hydration, antipyretics (acetaminophen or ibuprofen).
• Antifungal therapy is often not required; many recover spontaneously within 2–3 months.
• Close follow‑up with repeat chest imaging and serology at 4–6 weeks.

2. Moderate to severe pulmonary disease, or high‑risk patients

• Oral azoles – First‑line agents:
  • Fluconazole 400–800 mg daily (higher doses for severe disease).
  • Itraconazole 200 mg twice daily (alternative if fluconazole not tolerated).
• Therapy duration: 3–6 months for uncomplicated disease; longer (12–24 months) for chronic or disseminated infection.

3. Disseminated disease or central nervous system involvement

• Intravenous amphotericin B (liposomal formulation preferred) – 3–5 mg/kg daily until clinical stabilization.
• After initial amphotericin, transition to oral azole (fluconazole 800 mg daily or higher) for maintenance, often for 12 months or longer.
• Adjunctive measures: surgical debridement of bone or skin lesions if required, drainage of abscesses.

4. Special considerations

• Pregnancy – Avoid azoles (category D). Liposomal amphotericin B is the treatment of choice for severe disease.
• Renal or hepatic impairment – Dose adjustments, close monitoring of liver enzymes (azoles) and renal function (amphotericin).
• Drug interactions – Azoles inhibit CYP450; review concurrent medications (e.g., warfarin, certain statins, oral contraceptives).

Living with Coccidioidomycosis (Valley Fever)

Even after treatment, many patients experience lingering fatigue or lung changes. The following strategies help maintain health and quality of life.

Daily management tips

• Medication adherence – Use a pill organizer, set alarms, and keep a medication list.
• Follow‑up visits – See your clinician every 1–3 months initially; repeat serology and imaging as ordered.
• Vaccination – Keep influenza and COVID‑19 vaccines up to date to avoid superimposed respiratory infections.
• Pulmonary care – Perform deep‑breathing exercises, consider pulmonary rehabilitation if shortness of breath persists.
• Nutrition – Balanced diet rich in protein, fruits, vegetables; maintain a healthy weight to support immunity.
• Hydration – Adequate fluid intake helps thin respiratory secretions.
• Stress management – Chronic illness can be emotionally taxing; consider counseling, support groups, or mindfulness practices.
• Activity modification – Gradually increase activity level; avoid strenuous work that generates dust (e.g., construction, desert hiking) during active disease.

Monitoring red‑flag symptoms

Keep a symptom diary and alert your provider promptly if you notice worsening cough, new skin lesions, joint swelling, severe headaches, confusion, or unexplained weight loss.

Prevention

Because Valley fever is caused by an environmental fungus, complete avoidance is impossible in endemic regions, but risk can be markedly reduced.

Environmental measures

• Dust control – Wet soil before digging or demolition; use water trucks or misting systems.
• Protective equipment – Wear N‑95 respirators or higher when working outdoors in dust‑prone areas.
• Limit exposure during windy seasons – Spring and fall are high‑risk periods in the Southwest.
• Stay indoors during dust storms – Close windows, use air filters (HEPA).

Personal health actions

• Maintain a strong immune system – regular exercise, balanced diet, adequate sleep.
• People with known immune suppression should discuss prophylactic azole therapy with their physician during high‑risk seasons.
• Pregnant women in endemic zones should avoid dusty outdoor activities when possible.

Complications

If untreated or inadequately treated, coccidioidomycosis can lead to serious, sometimes life‑threatening problems.

• Chronic pulmonary infection – Persistent cough, fibrosis, or cavitary lesions that may lead to hemoptysis.
• Disseminated disease – Involvement of skin, bones, joints, or the central nervous system (meningitis).
• Septic arthritis or osteomyelitis – Bone destruction requiring surgical debridement.
• Meningitis – Can cause seizures, hydrocephalus, or death; requires lifelong antifungal suppression.
• Adrenal insufficiency – Rare, due to granulomatous infiltration of adrenal glands.
• Secondary bacterial pneumonia – Often follows the initial fungal infection.

When to Seek Emergency Care

---

Sources: Centers for Disease Control and Prevention (CDC). Coccidioidomycosis (Valley Fever), 2023; Mayo Clinic. Valley fever, 2022; National Institutes of Health (NIH). Clinical Practice Guidelines for Coccidioidomycosis, 2021; Cleveland Clinic. Fungal infections: Valley Fever, 2022; World Health Organization (WHO). Fungal diseases, 2020.

```